You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

267 Results
Guidelines and Advice
Status: Current
ID: GL 6-20
Version: 2
May 2023
Guidelines and Advice
Guidelines and Advice
Status: Current
ID: N/A
Version: 2
Jan 2023
Guidelines and Advice
Status: Current
Version: 1
Jul 2023
Regimen
Cancer Type:
Lung, 
Non-Small Cell, 
Small Cell
Intent: Adjuvant, Palliative
Funding:
ODB - General Benefit
    etoposide - oral capsules
Nov 2023
Regimen
Cancer Type:
Genitourinary, 
Bladder / Urothelial
Intent: Palliative
Jan 2023
Regimen
Cancer Type:
Genitourinary, 
Bladder / Urothelial
Intent: Palliative
Funding:
New Drug Funding Program
    Pembrolizumab - Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma
Jan 2023
Regimen
Cancer Type:
Genitourinary, 
Renal cell / Kidney
Intent: Adjuvant
Funding:
New Drug Funding Program
    Pembrolizumab - Adjuvant Treatment for Renal Cell Carcinoma
Mar 2023
Regimen
Cancer Type:
Gynecologic, 
Endometrial
Intent: Palliative
Funding:
New Drug Funding Program
    Pembrolizumab - Previously Treated MSI-H/dMMR Advanced Endometrial Cancer
Jul 2023
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Adjuvant
Oct 2023

Pages